ARIMIDEX

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Nigeria, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug ARIMIDEX contains one active pharmaceutical ingredient (API):

1	Anastrozole UNII 2Z07MYW1AZ - ANASTROZOLE
	Anastrozole is a potent and highly selective non-steroidal aromatase inhibitor. It inhibits the enzyme aromatase, which is responsible for converting androgens to estrogens. Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women.
	Read more about Anastrozole

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ARIMIDEX Film-coated tablets	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L02BG03	Anastrozole	L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BG Aromatase inhibitors
Discover more medicines within L02BG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8179L
BR	Câmara de Regulação do Mercado de Medicamentos	502300201115318
CA	Health Products and Food Branch	02224135
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00313704, 00564642, 00956106, 03931302, 05567705, 06919773, 07511985, 07511991
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	21650-1-11-04
EE	Ravimiamet	1033546, 1552722, 1552733, 1552744, 1552755, 1552766, 1552777
ES	Centro de información online de medicamentos de la AEMPS	2268001, 44-1296-97-C, 44579, 61286
FI	Lääkealan turvallisuus- ja kehittämiskeskus	386953
FR	Base de données publique des médicaments	62303214, 69890344
GB	Medicines & Healthcare Products Regulatory Agency	198662, 198723, 20074
HK	Department of Health Drug Office	42327
HR	Agencija za lijekove i medicinske proizvode	HR-H-226665669
IE	Health Products Regulatory Authority	12935, 12976, 12978
IL	מִשְׂרַד הַבְּרִיאוּת	4747
IT	Agenzia del Farmaco	031809015
JP	医薬品医療機器総合機構	4291010F1031
LT	Valstybinė vaistų kontrolės tarnyba	1002936
MT	Medicines Authority	PI908/09501B
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	263M98
NG	Registered Drug Product Database	04-7420
NL	Z-Index G-Standaard, PRK	45020
NZ	Medicines and Medical Devices Safety Authority	7569
PL	Rejestru Produktów Leczniczych	100080088
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W67720001
SG	Health Sciences Authority	09433P
TN	Direction de la Pharmacie et du Médicament	5683142H, 5683143H
TR	İlaç ve Tıbbi Cihaz Kurumu	8699586094163
US	FDA, National Drug Code	62559-670
ZA	Health Products Regulatory Authority	30/21.12/0495